OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance
Globe Newswire•27/10/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $72.7 million, up 19% year-over-year to a record
- ➤Full-year 2026 revenue guidance raised to $270.0-$273.0 million
- ➤Q3 adjusted EBITDA reached a record $6.9 million, versus $6.2 million
- ➤Q3 free cash flow generated $1.6 million, versus $3.4 million used previously
- ➤2026 outlook reiterates approximately $25.0 million adjusted EBITDA and breakeven free cash flow
Expert Statements
David Bailey, President & CEO of OrthoPediatrics
“In the third quarter, we continued to build on the momentum in our business, gaining share in Trauma and Deformity and Scoliosis globally, and continued substantial progress with our OPSB strategy. This quarter, we not only drove revenue growth, but we continued to improve profitability, and generated positive free cash flow. We remain confident in our ability to continue to drive these metrics forward,”
David Bailey, President & CEO of OrthoPediatrics
“Our innovation super cycle is an important part of that opportunity, with a strong pipeline of new products coming over the next several years that are expected to deliver higher value and improved capital efficiency. We believe these launches will be an important driver of our financial performance as we bring new solutions to more surgeons and hospitals. There are still significant unmet needs in pediatric orthopedics, and we believe OrthoPediatrics is well positioned to capitalize on that opportunity. Our focus remains on growing the business, improving our operating performance, and achieving breakeven or better free cash flow on an annual basis in 2026 and beyond while continuing to deliver innovative solutions for children.”
Record Third Quarter 2026 Revenue of $72.7 Million, Up 19% Year-over-Year
WARSAW, Ind., Oct. 27, 2026 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced its financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.